Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb

Molecular Therapy

Volumn 7, Issue 1, 2003, Pages 44-51

  Chang, David S ^a   Su, Hua ^a   Tang, Gale L ^a   Brevetti, Lucy S ^a   Sarkar, Rajabrata ^a   Wang, Rong ^a   Kan, Yuet W ^a   Messina, Louis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno associated virus; Angiogenesis; Gene therapy; Ischemia; VEGF

Indexed keywords

BETA GALACTOSIDASE; PARVOVIRUS VECTOR; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; COLLATERAL CIRCULATION; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HINDLIMB; LIMB ISCHEMIA; MALE; NONHUMAN; OXYGEN TENSION; RAT; SKELETAL MUSCLE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; ANIMALIA; PARVOVIRUS;

EID: 0037222484     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)00035-7     Document Type: Article

References (53)

1. Dormandy, J. A., and Rutherford, R. B. (2000). Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J. Vasc. Surg. 31: S1-S296.
2. Weitz, J. I., et al. (1996). Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94: 3026-3049.
3. Aquino, R., et al. (2001). Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J. Vasc. Surg. 34: 962-970.
4. Feinglass, J., et al. (1999). Rates of lower extremity amputation and arterial reconstruction in the United States, 1979 to 1996. Am. J. Public. Health 89: 1222-1227.
5. Takeshita, S., and Isner, J. (1994). Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93: 662-670.
6. Bauters, C., et al. (1994). Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am. J. Physiol. 267: H1263-H1271.
7. Tsurumi, Y., et al. (1996). Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94: 3281-3290.
8. Baumgartner, I., and Isner, J. (1998). Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123.
9. Isner, J. M., et al. (1998). Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg. 28: 964-973 discussion 973-965.
10. Rissanen, T. T., Vajanto, I., and Yla-Herttuala, S. (2001). Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb-on the way to the clinic. Eur. J. Clin. Invest. 31: 651-666.
11. Brevetti, L. S., et al. (2001). Administration of adenoviral vectors induces gangrene in acutely ischemic rat hindlimbs: role of capsid protein-induced inflammation. J. Vasc. Surg. 34: 489-496.
12. Fisher, K. J., et al. (1997). Recombinant adeno-associated virus for muscle-directed gene therapy. Nat. Med. 3: 306-312.
13. Kessler, P. D., et al. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93: 14082-14087.
14. During, M. J. (1997). Adeno-associated virus as a gene delivery system. Adv. Drug Deliv. Rev. 27: 83-94.
15. Berns, K. I. (1990). Parvovirus replication. Microbiol. Rev. 54: 316-329.
16. Chirmule, N., et al. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6: 1574-1583.
17. Su, H., Lu, R., and Kan, Y. W. (2000). Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc. Natl. Acad. Sci. USA 97: 13801-13806.
18. van Royen, N., et al. (2001). Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc. Res. 49: 543-553.
19. Semenza, G. L. (2000). HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88: 1474-1480.
20. Isner, J. (2000). Tissue responses to ischemia: local and remote responses for preserving perfusion of ischemic muscle. J. Clin. Invest. 106: 615-618.
21. Byun, J., et al. (2001). Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J. Mol. Cell Cardiol. 33: 295-305.
22. Deindl, E., et al. (2001). Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ. Res. 89: 779-786.
23. Welling, T., and Messina, L. (1996). Systemic delivery of the interleukin-1 receptor antagonist protein using a new strategy of direct adenoviral-mediated gene transfer to skeletal muscle capillary endothelium in the isolated rat hindlimb. Hum. Gene Ther. 7: 1795-1802.
24. 2 to a clinical ischemia index and histology in a rat model of chronic severe hindlimb ischemia. J. Vasc. Surg. 36: 172-179.
25. Takeshita, S., et al, (1994). Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90: II-228-II-234.
26. Buschmann, I., and Schaper, W. (2000). The pathophysiology of the collateral circulation (arteriogenesis). J. Pathol. 190: 338-342.
27. Hershey, J., et al. (2001). Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc. Res. 49: 618-625.
28. Banai, S., et al. (1994). Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89: 2183-2189.
29. Masaki, I., et al. (2002). Angiogenic gene therapy for experimental critical limb ischemia. Circ. Res. 90: 966-973.
30. Murohara, T., et al. (1998). Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101: 2567-2578.
31. Rivard, A., et al. (1999). Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 154: 355-363.
32. 165 gene transfer in the rabbit ischemic hindlimb model. J. Vasc, Surg. 32: 343-352.
33. Keyt, B. A., et al. (1996). The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271: 7788-7795.
34. Brevetti, L. S., et al. (2001). Exercise-induced hyperemia unmasks regional blood flow deficit in experimental hindlimb ischemia. J. Surg. Res. 98: 21-26.
35. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
36. Horowitz, J. R., et al. (1997). Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 17: 2793-2800.
37. Clauss, M., et al. (1990). Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172: 1535-1545.
38. Heil, M., et al. (2000). Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur. J. Cell Biol. 79: 850-857.
39. Arras, M., et al. (1998). Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 101: 40-50.
40. Ito, W. D., et al. (1997). Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ. Res. 80: 829-837.
41. Kalka, C., et al. (2000). Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res. 86: 1198-1202.
42. Kalka, C., et al. (2000). Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 97: 3422-3427.
43. Grosskreutz, C. L., et al. (1999). Vascular endothellal growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc. Res. 58: 128-136.
44. Wang, Z., Castresana, M. R., and Newman, W. H. (2001). Reactive oxygen and NF-κB in VEGF-induced migration of human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 285: 669-674.
45. Takeshita, T., Losordo, D., Kearney, M., Rossow, S., and Isner, J. (1994). Time course of recombinant protein secretion after liposome-mediated gene transfer in a rabbit arterial organ culture model. Lab. Invest. 71: 387-391.
46. Buschmann, I., and Schaper, W. (1999). Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News Physiol. Sci. 14: 121-125.
47. Conway, E. M., Collen, D., and Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49: 507-521.
48. Xiao, X., Li, J., and Samulski, R. J. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70: 8098-8108.
49. Springer, M. L., Chen, A. S., Kraft, P. E., Bednarski, M., and Blau, H. M. (1998). VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell 2: 549-558.
50. Lee, R., et al. (2000). VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102: 898-901.
51. Ruan, H., et al. (2001). A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 3: 255-263.
52. Matsushita, T., et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5: 938-945.
53. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council (1996). Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.